Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Core Insights - Kymera Therapeutics is advancing KT-474, a first-in-class IRAK4 degrader, aimed at treating immune-inflammatory diseases such as hidradenitis suppurativa (HS) and atopic dermatitis (AD) [3][4] - Sanofi plans to expand the ongoing Phase 2 trials for KT-474 based on preliminary safety and efficacy data, with the goal of accelerating progress towards pivotal studies [3][4] - The expansion of the studies is supported by interim analysis results and aims to inform future registrational trials [1][3] Company Overview - Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) to develop innovative therapies for critical health issues [5] - The company has pioneered the first heterobifunctional small molecule protein degrader for immunological diseases and is also developing oncology programs targeting undrugged proteins [5] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces and is committed to delivering effective oral small molecule degraders [5] Clinical Trials Information - The ongoing Phase 2 studies for KT-474 in HS and AD are registered under NCT06028230 and NCT06058156, respectively [2] - Sanofi is conducting randomized, placebo-controlled Phase 2 clinical trials of KT-474 in collaboration with Kymera, focusing on its potential therapeutic benefits [4]